HSP90AB1, also referred to as HSP90β, was reported to promote the angiogenesis [30–33] by activating VEGFRs transcription in an epithelial cell-dependent way or by interacting with Twist1, increasing nuclear translocation, and activating VE-cadherin transcription to induce EMT in HCC, suggesting that HSP90β might be a novel target for antitumor therapy. Here, HSP90AB1 is linked to hepatocellular carcinoma.